ArticleCVIR endovascular2026
Transarterial embolization for chronic wrist pain: a preliminary study of feasibility, safety, and pain reduction.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAbnormal neovascularization contributes to chronic musculoskeletal pain. This study aimed to evaluate the preliminary clinical outcomes based on pain reduction of transarterial embolization (TAE) for chronic wrist pain refractory to conservative management.
methodsThis retrospective study analyzed wrist TAE performed for persistent pain caused by triangular fibrocartilage complex (TFCC) injury, de Quervain's tenosynovitis, or extensor carpi ulnaris (ECU) and flexor carpi ulnaris (FCU) tendinopathy. Selective arterial embolization was performed using temporary gelatin sponge particles based on the anatomical distribution of symptoms. Pain severity was evaluated using the visual analog scale (VAS) at baseline, immediately after treatment, and at 1 day, 1 week, and 1, 3, and 6 months. Technical success was defined as embolization of at least one symptomatic artery. Clinical success was defined as a reduction of more than 50% in VAS score at 6 months.
resultsA total of 12 procedures were performed in 11 patients (median age, 40 years; interquartile range (IQR), 32-45.5). Diagnoses included TFCC injury (n = 8), de Quervain's tenosynovitis (n = 2), ECU tendinopathy (n = 1), and FCU tendinopathy (n = 1). Technical success was achieved in all procedures (100%). The median VAS score decreased from 6.5 (6.0-7.0) at baseline to 1.5 (1.0-3.25) at 6 months (p < 0.05). Clinical success was observed in 9 of 12 procedures (75.0%). Regarding safety, all adverse events were low-grade. These included transient erythematous skin reactions (Grade 1) in 58.3% (7/12) of cases, one case of puncture site pseudoaneurysm (Grade 2, 8.3%), and one case of brachial artery dissection (Grade 2, 8.3%). All events resolved without long-term complications.
conclusionsThe results of the current study suggest that TAE is a feasible and well-tolerated treatment option for chronic refractory wrist pain. While these preliminary findings are encouraging, larger prospective studies are warranted to validate clinical effectiveness and define optimal patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.